Amgen (AMGN) Tops Q3 EPS by 23c

Go back to Amgen (AMGN) Tops Q3 EPS by 23c

Amgen (AMGN) PT Lowered to $193 at Morgan Stanley Following 3Q

October 26, 2017 9:25 AM EDT

Morgan Stanley lowered its price target on Amgen (NASDAQ: AMGN) to $193.00 (from $196.00) while maintaining a Overweight rating following the company's 3Q release. Total revenues were slightly above ($5.77B vs. $5.74B cons), as were COGS (+$10M) and SG&A (+$20M), with R&D... More